[Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
- Published Article
Zhonghua fu chan ke za zhi
- Publication Date
Nov 01, 2010
These results demonstrated that siltuximab effectively block the IL-6 signaling pathways, which. Blockage of IL-6 signaling may provide benefits for the treatment of ovarian cancer.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/04/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/21211286